InhaleRx Secures Approval for Phase 1 Trial of Panic Disorder Therapy

InhaleRx Limited ( (AU:IRX) ) just unveiled an update.

InhaleRx Limited has received approval from the Bellberry Human Research Ethics Committee to commence a Phase 1 clinical trial for its investigational therapy, IRX-616a, aimed at treating panic disorder. The trial, which will be conducted at the CMAX facility in Adelaide, will assess the safety and pharmacokinetics of a synthetic CBD aerosol delivered via inhaler to provide rapid relief for panic attacks. This development marks a significant milestone for InhaleRx as it advances its clinical program with full funding from Clendon Biotech Capital, potentially offering a new treatment option for a condition with limited current therapies.

More about InhaleRx Limited

InhaleRx Limited is an Australian clinical-stage drug development company focused on creating rapid-onset inhaled therapies for unmet medical needs in pain management and mental health sectors. The company aims to secure U.S. FDA approval for its products using efficient regulatory pathways and has a funding partner providing up to $38.5 million to accelerate its development programs.

Average Trading Volume: 262,266

Technical Sentiment Signal: Hold

Current Market Cap: A$7.47M

For a thorough assessment of IRX stock, go to TipRanks’ Stock Analysis page.